PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
PHXM was delisted on the 8th of March, 2024.
5 hedge funds and large institutions have $5.97M invested in PHAXIAM Therapeutics S.A.. American Depositary Shares in 2022 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 4 closing their positions.
40% less capital invested
Capital invested by funds: $9.94M → $5.97M (-$3.97M)
44% less funds holding
Funds holding: 9 → 5 (-4)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$5.73K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.5M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$74.4K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$40K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$39.2K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $3.4M | -$1.5M | -79,349 | -29% |
|
|
BI
2
BVF Inc
San Francisco,
California
| $2.39M | – | – | – |
|
|
3
Jane Street
New York
| $93K | +$5.73K | +303 | +7% |
|
|
4
Citadel Advisors
Miami,
Florida
| $62K | -$74.4K | -3,936 | -54% |
|
5
Group One Trading
Chicago,
Illinois
| $19K | -$378 | -20 | -2% |
|
|
6
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$39.2K | -2,071 | Closed |
|
|
CS
7
Credit Suisse
Zurich,
Switzerland
| – | -$40K | -1,690 | Closed |
|
|
8
UBS Group
Zurich,
Switzerland
| – | -$8K | -358 | Closed |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| – | -$1K | -32 | Closed |
|
PHXM Hedge Fund Activity: Q1 2022 in Review
5 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) for Q1 2022, worth a combined $5.97M — down 40% from $9.94M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of PHXM and 0 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 1 added.
The largest buyer was Jane Street, adding an estimated $5.73K. The largest seller was Armistice Capital, cutting an estimated $1.5M.
- 5 institutional investors held PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) as of Q1 2022, down from 9 in Q4 2021.
- Funds reported $5.97M of PHAXIAM Therapeutics S.A.. American Depositary Shares stock for Q1 2022, down 40% quarter-over-quarter.
- 0 funds opened new PHAXIAM Therapeutics S.A.. American Depositary Shares positions in Q1 2022 and 4 closed out, a net change of -4 holders.
- The largest PHAXIAM Therapeutics S.A.. American Depositary Shares buyer in Q1 2022 was Jane Street, an estimated $5.73K added.
- The largest PHAXIAM Therapeutics S.A.. American Depositary Shares seller in Q1 2022 was Armistice Capital, an estimated $1.5M sold.
Based on aggregated 13F filings for Q1 2022.